This Review focuses on the two major origins of peritoneal macrophages, and describes how gastric cancer cells exploit their plasticity by metabolic signals, exosomal oncomiRs, paracrine factors and so on to push them into a pro-metastatic phenotype.
Abstract
Peritoneal metastasis is the most devastating form of progression of gastric cancer, characterized by strong immune suppressive properties and resistance to treatment. Tumor-associated macrophages (TAMs) are the main population of immune cells in the peritoneal cavity and participate in nearly every step of this process. In this Review, we focus on the two major origins of peritoneal macrophages (embryonic-derived GATA6+ resident cells and monocyte-derived CCR2+ cells), and we describe how gastric cancer cells exploit their plasticity by metabolic signals, exosomal oncomiRs, paracrine factors and so on to push them into a pro-metastatic phenotype. Reprogrammed macrophages proceed to participate in detachment of tumor cells, resistance to anoikis, escaping across mesothelium and stimulating angiogenesis and lymphangiogenesis, but also instigate an immunosuppressive environment suppressing T cell activity and increasing chemoresistance. Important molecular players that we describe here are CCL2/CCR2 and CSF-1/CSF-1R signaling axes, the STAT3/STAT6/PI3K axis and a complement-driven switch of TAMs from a cathepsin (CTS)-high to complement component 1q(C1q)-high state that promotes immune evasion. We also discuss the role of exosome-mediated cross-talk and give an overview of novel therapies against macrophages such as blocking their recruitment, reprogramming their polarization or using chimeric antigen receptor macrophage (CAR-M) therapy, typically in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) or immune checkpoint inhibitors. Bringing together the latest advances, we highlight key gaps in our understanding and suggest a direction for dismantling the macrophage-orchestrated metastatic niche with the ultimate goal of improving outcomes of this devastating disease.
This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.
Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al.· Signal Transduction and Targ...· 0 citations
Current evidence on TAM‐driven chemoresistance in GC is synthesized, highlighting the molecular interplay between TAMs, tumor cells, and stromal components and underscores the potential of TAM‐centric therapies to overcome resistance and improve clinical outcomes.
S. Abdul-Rahman, Abdulkareem Shareef, S. Jyothi et al.· Cell Biology International· 0 citations
Tumor-associated macrophages (TAMs) are key regulators of the tumor microenvironment, yet the functional specialization of TAM subsets in metastatic progression remains incompletely defined. Here, we characterized distinct TAM populations contributing to tumor-promoting mesothelial cell conversion in high-grade ovarian...
Sophie Heidemann, F. Finkernagel, A. Steitz et al.· Cell Death and Disease· 0 citations
Lung cancer remains the leading cause of cancer-related mortality worldwide, with metastasis, therapeutic resistance, and an immunosuppressive TME representing major barriers to successful treatment. Among the chemokine signaling networks implicated in these processes, the CCL2–CCR2 axis has emerged as an important reg...
Yu-Jie Huang, Jia Ma, J. Bi et al.· Frontiers in Immunology· 0 citations
It is suggested that tissue-adapted NETs serve as crucial microenvironmental cues that support the exit from quiescence and drive metastatic outgrowth, highlighting a promising perioperative therapeutic target for TNBC.
Taiko Kawakami, Yusuke Nakanishi, A. Suzuki et al.· Frontiers in Immunology· 0 citations
Background: Non–muscle-invasive bladder cancer (NMIBC) accounts for most newly diagnosed urothelial carcinomas and is characterized by frequent recurrences and a significant risk of progression despite transurethral resection and Bacillus Calmette–Guérin (BCG) therapy. Conventional risk models based on stage, grade, tu...
D. Diamantidis, G. Tsakaldimis, S. Giannakopoulos et al.· Bladder· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.